Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 5, 2007, Pages 453-461

  Antoniou, Katerina M ^a   Pataka, Athanasia ^b   Bouros, Demosthenes ^b   Siafakas, Nikolaos M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Angiogenesis; Apoptosis; Idiopathic pulmonary fibrosis treatment; Oxidative stress; Pathogenesis

Indexed keywords

AMINOGUANIDINE; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; APAFANT; BOSENTAN; CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; FG 1019; GAMMA1B INTERFERON; GC 1008; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INTERLEUKIN 13; LERDELIMUMAB; LUFIRONIL; MATRIX METALLOPROTEINASE; METELIMUMAB; NICOTINIC ACID; NITRIC OXIDE SYNTHASE INHIBITOR; PIRFENIDONE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2 DERIVATIVE; SILDENAFIL; SURAMIN; TAURINE; TETRATHIOMOLYBDIC ACID; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; EPITHELIUM CELL; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; LUNG ALVEOLUS EPITHELIUM; MYOFIBROBLAST; OXIDATIVE STRESS; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

APOPTOSIS; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; LUNG; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; PULMONARY FIBROSIS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 34447528599     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.01.002     Document Type: Article

References (85)

1. Gross T.J., and Hunninghake G.W. Idiopathic pulmonary fibrosis. N Engl J Med 345 (2001) 517
2. Selman M., King T.E., and Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134 (2001) 136
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161 (2000) 646-664
4. American Thoracic Society. ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002) 277-304
5. Bouros D. Current classification of idiopathic interstitial pneumonias. Monaldi Arch Chest Dis 55 (2000) 450-454
6. Antoniou K.M., Bouros D., and Siafakas N.M. Top ten list in IPF. Chest 125 (2004) 1885-1887
7. Bouros D., and Antoniou K.M. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 26 (2005) 693-703
8. Davies H.R., Richeldi L., and Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 3 (2003) CD003134
9. Kuhn III C., Boldt J., King Jr. T.E., Crouch E., Vartio T., and McDonald J.A. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 140 (1989) 1693
10. Kasper M., and Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Rev Histol Histopathol 11 (1996) 463-483
11. Simon R. Alveolar epithelial cells in pulmonary fibrosis. In: Phan S.H., and Thrall R.S. (Eds). Pulmonary fibrosis (1995), Marcel Dekker, New York 511-540
12. Iyonaga K., Miyajima M., Suga M., Saita N., and Ando M. Alterations in cytokeratin expression by the alveolar lining epithelial cells in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 182 (1997) 217-224
13. Selman M., and Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Rev Respir Res 3 (2002) 3
14. Plataki M., Koutsopoulos A.V., Darivianaki K., Delides G., Siafakas N.M., and Bouros D. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 127 (2005) 266-274
15. Uhal B.D., Joshi I., True A.L., et al. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 269 (1995) L819-L828
16. Waghray M., Cui Z., Horowitz J.C., Subramanian I.M., Martinez F.J., Toews G.B., et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J 19 (2005) 854-856
17. Selman M., Thannickal V.J., Pardo A., Zisman D.A., Martinez F.J., and Lynch III J.P. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64 (2004) 405-430
18. Carrillo G., Estrada A., Mejia M., et al. Inhaled beclomethasone and colchicine (IBC) versus inhaled beclomethasone, colchicine and captopril (IBCCAP) in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 161 (2000) A528
19. Lee C.G., Cho S.J., Kang M.J., Chapoval S.P., et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med 200 (2004) 377-389
20. Horowitz J.C., Lee D.Y., Waghray M., et al. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem 279 (2004) 1359-1367
21. Thannickal V.J., Flaherty K.R., Hyzy R.C., and Lynch III J.P. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs 10 (2005) 707-727
22. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., and Goldberg G.I. SV40-transformed lung fibroblasts secrete a 92 kDa type IV collagenase which is identical to that secreted by normal macrophages. J Biol Chem 264 (1989) 17213-17221
23. Panos R.J., Rubin J.S., Csaky K.G., Aaronson S.A., and Mason R.J. Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. Clin Invest 92 (1993) 969-977
24. Ulich T.R., Yi E.S., Longmuir K., et al. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 93 (1994) 1298-1306
25. Atabai K., Ishigaki M., Geiser T., Ueki I., Matthay M.A., and Ware L.B. Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. Am J Physiol Lung Cell Mol Physiol 283 (2002) L163-L169
26. Eitzman D.T., McCoy R.D., Zheng X., et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97 (1996) 232-237
27. Kubo H., Nakayama K., Yanai M., et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128 (2005) 1475-1482
28. Giri S.N., Hyde D.M., and Hollinger M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48 (1993) 959-966
29. Border W.A., Okuda S., Languino L.R., Sporn M.B., and Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346 (1990) 371-374
30. Wang Q., Wang Y., Hyde D.M., et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 54 (1999) 805-812
31. Siriwardena D., Khaw P.T., King A.J., et al. Human antitransforming growth factor beta(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 109 (2002) 427-431
32. Bonniaud P., Margetts P.J., Kolb M., et al. Progressive transforming growth factor {beta}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 171 (2005) 889-898
33. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nayure 425 (2003) 577-584
34. Singh J., Ling L.E., Sawyer J.S., Lee W.C., Zhang F., and Yingling J.M. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5). Curr Opin Drug Discov Devel 7 (2004) 437-445
35. Nakao A., Fujii M., Matsumura R., et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 104 (1999) 5-11
36. Vittal R., Horowitz J.C., Moore B.B., et al. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol 166 (2005) 367-375
37. Hildebrand A., Romaris M., Rasmussen L.M., et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302 (1994) 527-534
38. Giri S.N., Hyde D.M., Braun R.K., Gaarde W., Harper J.R., and Pierschbacher M.D. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 54 (1997) 1205-1216
39. Kolb M., Margetts P.J., Sime P.J., and Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 280 (2001) L1327-L1334
40. Antoniou K.M., Alexandrakis M.G., Siafakas N.M., and Bouros D. Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 22 (2005) 91-104
41. Kourbeti I.S., and Boumpas D.T. Biological therapies of autoimmune diseases. Curr Drug Targets Inflamm Allergy (2005) 41-46
42. Giri S.N. Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century. Annu Rev Pharmacol Toxicol 43 (2003) 73-95
43. White E.S., Thannickal V.J., Carskadon S.L., et al. Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10. Am J Respir Crit Care Med 168 (2003) 436-442
44. Wang Q., Wang Y., Hyde D.M., et al. Effect of antibody against integrin alpha4 on bleomycin-induced pulmonary fibrosis in mice. Biochem Pharmacol 60 (2000) 1949-1958
45. Bateman E.D., Turner-Warwick M., and Adelmann-Grill B.C. Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease. Thorax 36 (1981) 645-653
46. Seibold J.R., Korn J.H., Simms R., et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 132 (2000) 871-879
47. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040-1047
48. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360 (2002) 895-900
49. Rosenkranz S., Diet F., Karasch T., Weihrauch J., Wassermann K., and Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 139 (2003) 871-873
50. Raghu G., Safrin S., Weycker D., Starko K., and Bradford W.Z. Association of statins and angiotensin-converting enzyme inhibitor use with survival and diseases progression in patients with IPF. Am J Respir Crit Care Med 169 (2004) A706
51. Wang Y.J., Wang S.S., Bickel M., Guenzler V., Gerl M., and Bissell D.M. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol 152 (1998) 279-287
52. Godichaud S., Krisa S., Couronne B., et al. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. Hepatology 31 (2000) 922-931
53. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 18 (1963) 225-237
54. Keane M.P., Arenberg D.A., Lynch III J.P., et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159 (1997) 1437-1443
55. Keane M.P., Belperio J.A., Arenberg D.A., et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163 (1999) 5686-5692
56. Keane M.P., Belperio J.A., Moore T.A., et al. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 162 (1999) 5511-5518
57. Keane M.P., Belperio J.A., Burdick M.D., Lynch J.P., Fishbein M.C., and Strieter R.M. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164 (2001) 2239-2242
58. Renzoni E.A., Walsh D.A., Salmon M., et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 167 (2003) 438-443
59. Cosgrove G.P., Brown K.K., Schiemann W.P., et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170 (2004) 242-251
60. Renzoni E. Neovascularization in idiopathic pulmonary fibrosis. Too much or too little? Editorial. Am J Respir Crit Care Med 169 (2004) 1179-1180
61. Keane M.P. Angiogenesis and pulmonary fibrosis. Feast or Famine? Editorial. Am J Respir Crit Care Med 170 (2004) 207-209
62. Strieter R.M., Starko K.M., Enelow R.I., Noth I., and Valentine V.G. Idiopathic pulmonary fibrosis Biomarkers Study Group Effects of interferon gamma-1b on biomarker expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 170 (2004) 133-140
63. Bouros D., Antoniou K.M., and Siafakas N.M. Does interferon gamma-1b therapy improve survival in IPF via an angiogenetic pathway?. Chest (2005) (electronic letter to the editor)
64. Antoniou K.M., Alexandrakis M.G., Sfiridakι K., et al. Th1 cytokine pattern (IL-12 and IL-18) in BALF before and after treatment with interferon gamma-1b (IFN-γ-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc Diffuse Lung Dis 21 (2004) 105-110
65. Antoniou K.M., Tzortzaki E.G., Alexandrakis M.G., et al. Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis Vasc Diffuse Lung Dis 22 (2005) 204-209
66. Ziesche R., Hofbauer E., Wittman K., et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 (1999) 1264-1269
67. Raghu G., Brown K.K., Bradford W.Z., et al. A placebo-controlled trial of interferon gamma-1b inpatients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2004) 125-133
68. Antoniou KM, Polychronopoulos V, Dimadi M, et al. Comparison of interferon gamma-1b and colchicine in the treatment of idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomized study (poster presentation). In: The 99th international conference of the American Thoracic Society (ATS), Seattle, WA, May 16-21, 2003.
69. Bajwa E.K., Ayas N.T., Schulzer M., et al. Interferon gamma-1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 128 (2005) 203-206
70. Brewer G.J. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med 226 (2001) 665-673
71. Postlethwaite A.E., Holness M.A., Katai H., and Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin-4. J Clin Invest (1990) 1479-1485
72. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292;988-94.
73. Cantin A.M., Hubbard R.C., and Crystal R.G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 139 (1989) 370-372
74. Cooper Jr. J.A., White D.A., and Matthay R.A. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis 133 (1986) 321-340
75. Kuwano K., and Nakashima N. Oxidative stress in lung epithelial cells from patients with IIP. Eur Respir J 21 (2003) 232-240
76. Kuwano K., Miyazaki H., Hagimoto N., et al. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am J Respir Cell Mol Biol 20 (1999) 53-60
77. Crystal R.G. Oxidants and respiratory tract epithelial injury: pathogenesis and strategies for therapeutic intervention. Am J Med 91 (1991) 39S-44S
78. Beeh K.M., and Beier J. Glutathione deficiency of the lower respiratory tract in patients with IPF. Eur Respir 19 (2002) 1119-1123
79. Hunninghake G.W. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 353 (2005) 2285-2287
80. Demedts M., Behr J., Buhl R., et al., IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353 (2005) 2229-2242
81. Gurujeyalakshmi G., Iyer S.N., Hollinger M.A., and Giri S.N. Procollagen gene expression is down-regulated by taurine and niacin at the transcriptional level in the bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 277 (1996) 1152-1157
82. Zhang X.Y., Shimura S., Masuda T., Saitoh H., and Shirato K. Antisense oligonucleotides to NF-kappaB improve survival in bleomycin-induced pneumopathy of the mouse. Am J Respir Crit Care Med 162 (2000) 1561-1568
83. Gurujeyalakshmi G., Wang Y., and Giri S.N. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 4 (2000) 399-411
84. Hyde D.M., Giri S.N., Schiedt M.J., and Krishna G.A. Effects of three cysteine pro-drugs on bleomycin-induced lung fibrosis in hamsters. Pathology 22 (1990) 93-101
85. Tzouvelekis A., Patlakas G., and Bouros D. Application of microarray technology in pulmonary diseases. Respir Res 5 (2004) 26